





...F...
...L... ,F... P...
...L... ,F... P...
...L... ,F... P...

... ,P... C... E... O... F... P...

2016 Corporate Social Responsibility Report

CONTENTS

04 A R

14 A



42 H



90 C



112 P I S I

115 F F

116 T C N

121 T P E

06 H 2016

32 E



56 I



102 C



122 G O C S R
P (GB36002)

131 G R I G4I I

140 A S SGS

Highlights of 2016

July	August	September
------	--------	-----------


<p>I J , F P 86%</p> <p>G P</p> <p>G P</p> <p>I</p> <p>FDA S .T</p> <p>F P</p>	<p>I A ,F H I</p> <p>F P ' H</p> <p>C C H</p> <p>C B H</p> <p>F P ' H G A C</p>	<p>I S ,F P</p> <p>I S S .B</p> <p>S</p> <p>S\$100</p> <p>T</p> <p>T</p> <p>.T D</p> <p>S</p> <p>I S</p>
--	---	--

Rewards and Recognitions



Industry Ranking Category

- July • **Top 100 Pharmaceutical Industry Enterprises of China**
China National Pharmaceutical Industry Information Center of Ministry of Industry and Information
- September • **Ranked 3rd among the Top 100 Strengths of Pharmaceutical Research and Development in China, ranked 2nd among the Strengths of Biopharmaceutical Research and Development in China**
YAOZH.COM
- November • **Ranked 14th among the Top 100 Companies in China Pharmaceutical Industry**
CFDA South Medicine Economic Research Institute, Medicine Economic News
- November • **Top Ten Pharmaceutical Industry Enterprise Group of China**
China Pharmaceutical Industry Association, China Association of Pharmaceutical Commerce
- November • **Top 100 Future Enterprises in China**
ACCA (The Association of Chartered Certified Accountants)
- November • **Most Innovative Multinational Companies**
Bioclub



Marketing & Sales Category

- January • **Best Investor Relations Award**
Awarding Institution: China Financial Market Financial Magazine
- June • **The Best Overseas Medical Investment Enterprises**
Awarding Institution: China Chamber of Commerce for Import and Export of Medicines and Health Products
- October • **Top 20 Most Competitive Listed Pharmaceutical Companies in China, Top 10 Listed Pharmaceutical Companies with the Highest Investment Value**
Awarding Institution: China Pharmaceutical Enterprise Management Association
- November • **Best Listed Companies in Pharmaceutical Industry**
Awarding Institution: Value Line, China Economic Net, China reform Daily

Corporate Social Responsibility Category


- January • **The Best Social Responsibility Brand**
Awarding Institution: Media of the Fifth Charity Festival
- July • **Responsibility Innovation Best Case Award for the Year**
Awarding Institution: Jiefang Daily (Shanghai Observer), Shanghai Daily, etc.
- December • **Corporate Social Responsibility of Listed Companies**
Ranked 2nd in CSR Development Index and ranked 1st in Report Appraisal Results
Awarding Institution: SSRB, Shanghai Stock Exchange, Xinhuanet, Shanghai Association of Listed Companies, etc.
- December • **Golden Bee Excellent CSR Report 2016 Leading Enterprise Award**
Awarding Institution: MOC China WTO Tribune




M



F P , C ,
1994 S S E (:
600196-SH) A 1998 M B S E
H K L (: 02196-HK) O 2012. F
F P G
C . T G
R&D,
A G , F
P G R&D
S , C , T S F ,
S T G R&D
I C , F P G
I
G , F P
G C , F P G
F P
S , C
F P G
F P
P G , F
P G
F P



为爱飞
向上海市福利





G a a d S r a e g

F P G '
 F , R&D,
 S ,
 L ,
 M&A .

S G

S - A C .



M - AC .



D -

S D S




S - C F P G ' C ,




M - I



B F P G F P G





Combining Capital and Management to Drive Global Resource

Leveraging our global footprint, we are focused on driving growth in emerging markets, particularly in the Asia-Pacific region. Our strategic initiatives are designed to enhance our operational efficiency and expand our market reach. By investing in local infrastructure and talent, we aim to create sustainable value for our stakeholders.

Furthermore, we are committed to environmental, social, and governance (ESG) excellence. Our ESG framework is integrated into our core business strategy, ensuring that we meet the highest standards of ethical conduct and social responsibility. This commitment is reflected in our transparent reporting and active engagement with our stakeholders.

Corporate Management

F P G
M C C P D C M D C T M S
M C S F P I T
F P
G
T C
D S S P C D B L S D T M B
M S D P F D D C I P D R&D C EHS
D D C B P M D D C B P A D D H M R
D D I R P C D D I A B D S
D D I C D C (R) I D M M S
C I C /F H I C M D M M D
M I 2016, C
D O M D C M T D D T
G P A
T
I D C I M C C O M E C
B M C C C A C C B P M C
C EHS M C S C I 2016, C
M C I M C O

Corporate Governance

I C L S L C C G L
C CSRC L R SSE, A 14 C G C L
L R S E
A :T
C C C T
C T B D S
A B D :T C A
B D A A

A : T C

A : T C

A M I D L C CSRC, G M S


S E I D L C SSE, G A S

R I D D L C SSE, R A S

M E S D E I C M C S I

D I , A S M E A R I

C , S R R S - A R I C



27

Life expectancy at birth, female

In 2016, Female Population Reference Group A-C had a life expectancy at birth of 42 years, compared to 23 years for the reference group C.

Age-specific fertility rate, female

In 2016, the age-specific fertility rate for the reference group A-C was 1.7, compared to 1.7 for the reference group C.

Digital divide for Africa

In 2016, the digital divide for Africa was 1.7, compared to 1.7 for the reference group C.

The C40 Cities and the future of the world

The C40 Cities and the future of the world, 2016.

Materia A a

F P

I 2016, F P

C (CSR)

(EHS,) (C)

M CSR F P 2016 C

Ide , ca f , e

S 30

F a f , e ba

I e e a de ca ge

C 200

A e e a da a f , e

S e e g a d a e e


E

S e e g f a e a , e

A r a a d c r a

C

Re d g a e a , e




- | | | | |
|-----|--------|------|--------|
| 1 P | 9 A -C | 17 C | 25 C |
| 2 R | 10 I | 18 C | 26 C |
| 3 O | 11 Q | 19 G | 27 T |
| 4 Q | 12 T | 20 G | 28 A - |
| 5 S | 13 P | 21 C | 29 I |
| 6 R | 14 I | 22 R | 30 C |
| 7 C | 15 H | 23 P | 31 C |
| 8 C | 16 M | 24 | 32 D |

Sistema de Gestão da Qualidade

F. P. ... E. ...
 F. P. ... CSR ... G. ...
 F. P. ... G. ... S. ... C. ... P. ... I. 2016, F. P. ...
 CSR ... A. ... GE ... L. ...
 I. J. 2016, 12 I. ... F. ... C. ... S. ... R. ... C. ... TOT. ...
 M. ... C. ... PRC ... G. ... B. 2030 S. ... R. ... A. ... F. ...
 P. ... S. ... G. ... C. ... C. ... S. ... P. ... G. ... I. (C. ...), D. P. ... C. ...
 ...
 ...

Participação e Eficiência da Gestão de Recursos Humanos e da Qualidade

O 10 M. ... C. ... P. ... E. ... A. ... C. ... P. ... I. ... A. ... C. ...
 A. ... M. ... D. ... I. ... C. ... P. ... C. ... A. ... C. ... A. ...
 T. ... C. ... M. ... C. ... N. ... P. ... M. ... A. ...
 CSR P. ... G. ... P. ... E. ... C. ... B. ... T. ...
 CSR ...
 F. P. ... CSR P. ... G. ... P. ... E. ... C. ... O. 3 A. ... F. ...
 P. ... CSR ... C. ... EHS. ... F. P. ... F. P. ...
 ...
 CSR ...












CSR Management

F. P. ... G. ... CSR ...
 ...
 CSR P. ...
 F. P. ... G. ... T. ... G. ...
 ...
 G. ... F. P. ... G. ...
 ...

CSR M P



Sa e der

S	E	F	P	R	F	P
 S	S P O			I T E C		
 C	P P P			P M C E E P		
 M /	M S			E C E T		
 E	P P C			E E E O S S		
 S	A J			E C G		
 G	F L F			O C P A P		
 C /	C S C			A P A		
 P /	T C			O C		
 P	F S			C C P		

State of the Emergency

State of the Emergency

I have been thinking about the state of the emergency for a long time. I have been thinking about the state of the emergency for a long time. I have been thinking about the state of the emergency for a long time. I have been thinking about the state of the emergency for a long time. I have been thinking about the state of the emergency for a long time.

I have been thinking about the state of the emergency for a long time. I have been thinking about the state of the emergency for a long time. I have been thinking about the state of the emergency for a long time. I have been thinking about the state of the emergency for a long time. I have been thinking about the state of the emergency for a long time.

S

I 2016, F P P B S P
T M S F P (G) C, L T L
P M A I S F P (G) C, L
T ;

F P
;
;

A
F P G

Peer

F P
I 2016, F P
;

I J, F P CIMC, M G
2016 A M C E A -F A
;

I S F P C C
B
I N A
;

I O, F P 2016 F P B I
C I S T I C S
C F P F P
;

I D 9 G B I F CSR R C 12
I F S R C TOT, F P
CSR

Partners and

F P
I 2016,
F
P

F P P
I S P F P S C
S J C
P T P F P S
P P S P D, P T S
P T

C, -g e e a rga a

I 2016, F P G 35
;

I 2016, G 100
;

T 90
;



C 35



T 90

TeP b c

F P ;

T F P , C F P (L I),

I 2016, F P ;

F P G C

F P G F

P B P R D

I 2016, F P F P I S , I

G ;

F P I 2016, 250,471

P I S A G

Real Reg er e

F P 2016 P C L O D

C B 2016 M S C I D M C

100 C 30

F P Q D M C 2016 30

P 20 I

P

F P A M R P A P L ,

T P I C , M I I 13 F - P ,

S CPPCC S CPPCC

P D P H I

S

T D R D D CFDA C T S C T M S D

P M D B ,

A

T R E G L B B - I , R&D

P H , S C P P P

S

H P S T P S C T


N F S D T A I C A A

T S C A A ;


G H P S B C

G H

.....





ca l dca fF P a aGr



fr b e eg e



re eac a dde e





I 2016, F P G

I 2016, G

16.02%

2015; G

RMB14,628.82

RMB10,259.54

14.83%

2015. T G

RMB3,571.55

RMB2,805.84

L C

RMB2,092.78


5.92%, 14.05%

26.36%

2015

R&D Performance

R&D Investment of Fosun Pharma Group for 2012-2016 (RMB1,000,000)



2016

2015


2014

2013


2012

In 2016, R&D investment reached RMB1,106 million (an increase of 33.23% compared with 2015). R&D investment accounted for 6.67% of total operating income.

R&D Investment




R&D Pipeline



Patent Application



Patent Application and Factoring



T A M P

T A	P	INN	I
M	A	R P G	F B
	S L	P I	F II
	S P	G T	F II
	B	R E H I	F
	L T	F	F
	N/A	C	F
C	A	M C A I	T
	D E	A I D E	T
	K	D	T
	B T	H I	T
	B T	T	F
	B	P	H
B	M	C	F
	A D J	D I C B	T ()
	Q	Q T F	T
A	ARTES NPL S	A P	M M
	ARTES N		
	C C	C S	T
A	S D L K		I
	N N K	E P I H R T	F
	N/A	R	I
	Q S S L	P S S	F
	E B		

Healthcare Service

I 2016, RMB1,677.56, 21.67% 2015. I 2016, G

I 2016, P II Q Q H S H G G H C H G B H) (T G C M G G S F G J Q C L T B M O20 A H , G H H) (C H , J C H , G , 3,018. F G F H C (CHD). I 2016, F H B , S T G F H Q S P F H G

Medical Device and Medical Drug

I 2016, G .T RMB2,663.91, 18.17% 2015. I 2016, A L C I I 2016, A L RMB786.21, 14.19% 2015. I R&D I 2016, A L 6 E CE 2 2016, S. FDA S E A L 2016, G S G I 2016, G CML D 2016, 2016, D I 19,000 2016, M C H K , 54% 2015. M C I S I S 0.05 (T1 0 () 3) 5 .6 () 0 .6 (4 () 0.5 7.6 () 10.0.050.011) 4.1 (0.4 () 0.5) 0.011 50.5 (ML ((6 () T 0.9 ()) 4.019- (.9 (D) 34 ()) 0 ML (() 4 () 6 .004 T 0 () 6 (8618) 0.05 () -25

Partnership and Research

In 2016, Sinochem Group continued to strengthen its cooperation with international organizations and institutions. Sinochem Group signed a cooperation agreement with the United Nations Development Programme (UNDP) to jointly launch the "Sinochem-UNDP Partnership for Sustainable Development" project. The project aims to promote sustainable development in China and the world through the cooperation of Sinochem Group and UNDP. The project will focus on the fields of environment, health, and education. Sinochem Group will provide technical support and financial assistance to UNDP's projects in these fields. UNDP will provide Sinochem Group with information and advice on sustainable development. The project will be implemented in China and other developing countries. Sinochem Group will also cooperate with other international organizations and institutions to promote sustainable development.

Great achievements in M&A and integration

In 2016, Sinochem Group continued to strengthen its cooperation with international organizations and institutions. Sinochem Group signed a cooperation agreement with the United Nations Development Programme (UNDP) to jointly launch the "Sinochem-UNDP Partnership for Sustainable Development" project. The project aims to promote sustainable development in China and the world through the cooperation of Sinochem Group and UNDP. The project will focus on the fields of environment, health, and education. Sinochem Group will provide technical support and financial assistance to UNDP's projects in these fields. UNDP will provide Sinochem Group with information and advice on sustainable development. The project will be implemented in China and other developing countries. Sinochem Group will also cooperate with other international organizations and institutions to promote sustainable development.

A
(C

F P G

L F P (RMB10,000)

O * T

2016		1,873	2,001	7,614	841	225,356
2015		6,345	1,519	4,962	3	200,597
2014	20,678	4,759	1,408	4,850	285	163,190


*N

We, Genavc Health

J 2016, G H .T
C .T
C .T
C F

Y. G a g a Med ca I e e e Ma age e C a L ed

G M I M
C L
F H I N .1
P N .1 P C F P
T
A
B H C H
-4 12 4



爱满新世界 暨爱满之夜

O 9 S , S , S O C F , F
F F C N : L L F N A R C
S S C S


... ..
... ..
... ..
... ..

M S C F

I A T

M.L





Service framework

P F P S A 2016, F P R
A T G EHS
F P
M
R F P G
C T C
C T C
C
F P G
R&D,
M
R&D,
H F P G G M
3,018 I 2016,


Corporate framework

I 2015, G P D M Q M F E L Q
C P P M L
I 2016, G GMP GMP GMP
B T 2016
I 2016, O M D G O P Q
A I C F P 13
P I 2016, 14 B E G P
T
T O M D CAPA
F GMP, GMP, G
G OOS
F P
I 2016, G 58
A 2010 GMP 401 GMP T
I 2016,
M F P G
T M I S M R



M

3,018



I 2016, O A
P Q A F
I C 13
P 14



100%

401 58

.T
 .E
 I 2016,
 CE
 .A
 F P
 .A

ISO13485

I	S	P	S	F	P	G	D	F	A
S	I	D	F	S	A	R			
H	P	0	16	P					
A	P	2	14	P					
A		3	0	P					
F		7	5	P					
H	P	5	33	P					
B		1	22	P					
T		2	15	P					
P		0	39	P					
C	B	5	1	P					
J		4	0	P					
S		3	1	P					
S	S	1	0	P					
D	P	2	13	P					
E	P	2	60	P					
G	P	9	39	P					
P		5	136	P					
C	P	2	7	P					
H	P	0	0	P					
R	P	4	0	P					
S	H	2	0	P					
T		58	401	P					

S	C	R	I	M	D	S	F	P	G
S	D	A	I	S	A	R			
P	E	F	2016	.S. FDA	C	(II),	(I),
					(III),	(I),	O
					(),	(I),	EIR
					(I)			
P	A	2016	.S. FDA)	(O
									EIR
C		M	2016	.S. FDA	I	A	(F	P	
R					T	R	,N	D	
I									
G	P	M	2016	HO	A				P
		M	2016		P	(OSD-I			
G	P	M	2016		P	(INJ-I	INJ-II		P
H	M	12 16J	2016	D N	ISO13485 C	,CE C	C II ,CE C		Q
				(DN)	C II ,CEC	C III			
S		24 26A	2016	T R	EN ISO9001, EN ISO13485, CE C		P		Q
T									
L		30 31M	2016	T R	EN ISO 13485, EN I13485:2012/AC				Q
T				LGA P					
				G H					
N						E	A		



Medical device efficacy

T G

T G

A D R R M 2016, G S

P

G T G F

G

T G

I 2016, F P G

2016. A 18 P

Certification of products

I 2016, G

78 P G 2010 GMP 61 API 53

T , 13 API G

H , L (MHL) G FDA S , E , J , M

2 API (5 API) G P

HO-PQC 1 FDA S

13^{API} achieved cGMP Certification

1

2^{API} (5 API)


G P

HO-PQC 1

C S FDA P H

F

P



H					'C					M					D					S					F					P					G				
N					T					N					R																								
L	M	M	F	B											5														5								100%		
			B												2														2								100%		
			C	M											0														0										
															0														0										

Ha d g fU er 'C a

T
T

.T

.T

.C

2016,

G

72

.I

A

M

P

F

P

G

.A

/

.A

.C

.C

A

Pr d cMeca

E

G

2016,

G

8

.I

E

I 2016,

F

P

G



100%

100%


8

0

I 2016,

G F P

Marijuana Access




C

>40,000

H
>5,100

O
>2,000



Q a Safe Tra g

I
G
K
GMP
I 2016, G A
23
I R S A F
M D
P G

Social Management

Social Management is a process that involves the identification, analysis, and management of social risks and opportunities. It is a key component of corporate social responsibility (CSR) and is essential for the long-term success of any organization. Social management involves a variety of activities, including stakeholder engagement, social impact assessment, and the development of social policies and procedures. The goal of social management is to ensure that the organization's operations are socially responsible and that it contributes positively to the communities in which it operates.

In 2016, the company continued its commitment to social management by implementing a number of initiatives. These included the development of a social management framework, the establishment of a social management committee, and the implementation of a social impact assessment process. The company also engaged with its stakeholders to identify social risks and opportunities and to develop strategies to address them. As a result of these efforts, the company was able to identify and manage a number of social risks and opportunities, and it was able to implement a number of social management initiatives that have had a positive impact on the communities in which it operates.

The company's social management framework is based on the following principles:

- Transparency: The company is committed to transparency in its social management activities and to providing regular updates on its progress.
- Stakeholder Engagement: The company is committed to engaging with its stakeholders and to listening to their views and concerns.
- Social Impact Assessment: The company is committed to conducting social impact assessments of its operations and to using the results of these assessments to inform its social management activities.
- Social Policies and Procedures: The company is committed to developing and implementing social policies and procedures that are consistent with its social management framework.

The company's social management committee is responsible for overseeing the company's social management activities and for ensuring that the company is compliant with its social management framework. The committee is composed of representatives from the company's senior management and from its stakeholders.

The company's social impact assessment process is designed to identify and assess the social impacts of the company's operations. This process involves a number of steps, including the identification of potential social impacts, the assessment of the likelihood and severity of these impacts, and the development of strategies to address them. The results of the social impact assessment process are used to inform the company's social management activities and to ensure that the company is taking appropriate measures to address social risks and opportunities.

The company's social management initiatives have had a number of positive impacts on the communities in which it operates. These include the creation of new jobs, the improvement of local infrastructure, and the provision of social services. The company is committed to continuing its social management efforts and to ensuring that it continues to make a positive contribution to the communities in which it operates.

In 2016, the company continued its commitment to social management by implementing a number of initiatives. These included the development of a social management framework, the establishment of a social management committee, and the implementation of a social impact assessment process.


557

447

110

The company's social management framework is based on the following principles:

671



S . M . M P . . S . . F P . G . 2016

S G . . P B A . . P E . . P P

006010

25

O T P F P S

Patient-Centered Medical Service

The company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.

Medical Service and Education

In 2016, the company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.

The company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.

In 2016, the company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.

The company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.

In 2015, the company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.

The company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.

The company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.

In 2016, the company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.

The company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.

The company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.

Drug Use Management

The company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.

The company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.

The company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.

Medical Service and Education

The company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.




Service Center



In 2015, the company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.

The company has established a patient-centered medical service system, which is a key to improve the quality of medical services and enhance the patient's satisfaction.





95.39%

.T ()
D 2016,
M
17.
A ()
95.39%. C H F P C JKB),
G P (N H
(G P H F P
C). 2016.

A
F P G

C S S M S S F P G


S	J. C H	G H	H	C H	H G
S	97.8%	95%	95%	96.8%	92.32%


M F P

S	G H	C H	H	J. C H	H G
M	9	5	3	0	0

N :T

R P A S P C H (G P)











O C ' D , F P



F P G & E , H & S (EHS)



C O A EHS
H T R S

Environment, Health and Safety (EHS) Policy

EHS

For the purpose of this policy, the following definitions shall apply:

Environment: The natural and built environment, including air, water, soil, and the natural resources.

Health: The physical and mental well-being of employees.

EHS



1. Company's EHS Policy is to protect the environment, health and safety of employees, and to prevent pollution and environmental damage.

EHS



2. The company shall ensure that all activities are conducted in a manner that is consistent with the EHS policy.



3. The company shall ensure that all activities are conducted in a manner that is consistent with the EHS policy.



4. The company shall ensure that all activities are conducted in a manner that is consistent with the EHS policy.



5. The company shall ensure that all activities are conducted in a manner that is consistent with the EHS policy.

EHS

EHS

EHS



6. The company shall ensure that all activities are conducted in a manner that is consistent with the EHS policy.

EHS

EHS

EHS

For the purpose of this policy, the following definitions shall apply:

EHS

EHS

EHS

Exerg C

- 1) 8,769,376 52,439 0.6% 2015. I 139,000 2016 1.61% 2015. T 5.99 / RMB10,000, 1.9 24.1% D 2016, S S 396,000
- 2) E 478,175,186 53,707,564 12.7% 2015. I 2016, D P , F L T S S , G 2016.
- 3) O 185,690,272 12,276,649 7.1% 2015. O 126.93 /

C E / C F P G

	T (³ /)	T (/)	E (/)	T (/)	O (/)	E ()	RMB10,000	RMB10,000
								(³ /RMB10,000)
2012	6,175,823	249,387,502		79,928,627				
2013	7,777,884	365,006,317	44,859,276	120,177,461	165,036,737			
2014	8,377,364	421,765,752	51,835,011	122,713,255	174,548,266	171.56		8.23
2015	8,716,937	424,467,622	52,209,518	121,204,106	173,413,623	157.01		7.89
2016	8,769,376	478,175,186	58,815,548	126,874,724	185,690,272	126.93		5.99

C C	M O	E E	C C	M S (GBT2589-2008)	F P	G	2016 (R	G	P
S	T	T	E	T					
(³)	()	()	()	()					
B	204,303	9,100,000	1,119,300	2,431,044					
J	114,315	8,030,000	987,690	2,454,958					
P	92,698	6,385,400	785,404	1,051,983					
C B	59,910	7,021,980	863,704	1,102,893					
F	8,960	1,353,675	166,502	512,647					
S	24,310	333,900	41,070	102,515					
D P	391,608	9,358,414	1,151,085	8,040,063					
A	61,388	5,118,909	629,626	1,214,438					
G P	720,702	30,072,609	3,698,931	6,550,133					
S S	4,603,314	292,250,000	35,946,750	87,430,320					
H P	39,259	2,634,503	324,044	451,782					
A P	123,433	7,078,740	870,685	2,818,551					
H P	45,236	1,021,655	125,664	596,698					
E P	285,663	16,096,174	1,979,829	3,024,794					
C P	123,820	6,018,550	740,282	1,010,622					
P	348,581	29,640,192	3,645,744	3,808,225					
T	12,952	29,119	3,582	265,678					
T	109,823	513,300	63,136	272,628					
S H	12,166	2,885,625	354,932	918,496					
S T P	972	5,768,580	709,535	4,941					
C R I	42,387	1,247,716	153,469	64,617					
R P	12,543	2,416,970	297,287	422,558					
F P	2,857	220,420	27,112						
G H	221,800	2,789,010	343,048	226,003					
H	132,141	4,555,651	560,345	29,619					
C H	511,000	11,930,000	1,467,390	1,187,084					
J C H	185,316	1,666,000	204,918	95,700					
G H	136,888	1,942,106	238,879	1,924					
C M	820	246,443	30,312	531					
B	6,531	804,042	98,897	6,938					
L M M	5,613	1,858,608	228,609	21,369					
F B	935	309,768	38,101	122					
	1,044	158,182	19,456						
F M S	561	157,114	19,325	4,900					
H M	34,500	1,218,783	149,910	36,813					
C (B)	335	47,717	5,869						
C S	180	20,151	2,479	6,083					
S T	36,885	2,884,972	354,852	390,632					
L T	50,000	2,060,000	253,380	316,422					
A	3,623	925,208	113,801						
C T	4	5,000	615						

B	E	C	M	S	F	P	G	2016			
N		E	N	L	C	S	R	C	D	G	F
		()	(³)	()	(³)	()	()	()	(L)	(L)	()
	B	9,100,000		15,600		27,112,000			200	74,300	
	J	8,030,000		8,400		28,458,000					
	P	6,385,400	5,338			11,997,000				15,080	
C	B	7,021,980				12,629,320			5,301	12,569	
	F	1,353,675	353,787	2,313					180	35,700	
	S	333,900		1,800		955,000				16,500	
D	P	9,358,414	1,283,596				8,855,000		350	6,898	
	A	5,118,909		2,890		13,867,860				18,991	
	G	P	30,072,609	805,820			7,649,000		1,078	12,614	
	S	S	292,250,000				122,400,000				
H	P	2,634,503		2,400		4,983,300			400	18,650	
A	P	7,078,740		10,617	5,009,029				139,324	51,484	
H	P	1,021,655		5,550					21,849	28,081	371,530
	E	P	16,096,174	831		34,829,000			4,008	29,705	
C	P	6,018,550	41,846			11,135,340					
	P	29,640,192	2,835,488						5,780	28,233	
	T	29,119				2,979,000				9,600	
	T	513,300	109,820						76,393	31,649	
S	H	2,885,625							750,000	5,636	
S	T	P	5,768,580							4,651	
C	R	I	1,247,716	36,020						15,730	
	R	P	2,416,970			4,920,300			400	100	
F	P	220,420									
G	H	2,789,010	156,250						6,569	9,600	
	H	4,555,651								8,289	14,569
C	H	11,930,000	854,000						14,924	31,164	
J	C	H	1,666,000	48,985					5,900	22,000	
	G	H	1,942,106						10	1,800	
C	M	246,443								500	
	B	804,042								6,531	
L	M	M	1,858,608						100	20,000	
F	B	309,768							100		
		158,182									
F	M	S	157,114						360	4,200	
H	M	1,218,783							12,820	19,970	
C	(B)	47,717									
C	S	20,151							5,000		
S	T	2,884,972							316,000	5,800	
L	T	2,060,000	237,911								
	A	925,208									
C	T	5,000									

I 2016, F	P	G	A
		G	RMB7,000,000
28,600	461,000	3	5,300,000

M E -S M

Diagram illustrating the process of reading a word (likely 'Ergage') by a child, showing the sequence of letters and syllables being processed.

Stage 1: A ca f e e erg - a g (ec ge)

Stage 2: E erg a age e e e d

Stage 3: A a e e f e erg - a g E e e (E gage e e)

M E S E R S F P G 2016

E					A		R
N	A			O	E	(RMB10,000)	
B		I		1.	E	50.4	
				2.	700,000		
P	R			A	E	91.5	
C	B	1.			E		
		2.HECC			S	83	
F		S		1.	E		
				2.	17,000		
S				O	E	0.7	
D	P	I	1.		E		
			2.		S	21.5	
			3.		S		
A	1.	C			E	24.84	
	2.HECC				S		
G	P	1.			E	103	
S	S	2.HECC			S		
H	P	I		E	E	36.25	
H	P	I		L	S	8.61	
E	P	1.	LED	S	E	10.2	
		2.					
P	S	PLC	1.		E	5.98	
			2.		S		
T	C	LED	I		E	7.07	
C	R	LED		S	E	1.12	
G	H	A			N	10	
C	H	1.	LED		E	6.8	
		2.		R	N	171.3	
J	C	H	A		E	10	
L	M	M		A	E	16	
F	B			S	E	0.1	
H	M			S	E	0.01	
C	(B)			S	E	2.97	
S	T	A		F	E	0.05	
			1.				
			2.		E	36	

$$* N : D$$

Uganda water service company

In 2016, the Group's water supply and sewerage services provided to customers in the region of Kampala, Uganda, were valued at 8,769,376 (USD),

representing an increase of 6.42% compared to the value of 8,238,000 (USD) recorded in 2015. This increase was due to the increase in the number of customers served by the Group, which was 10,000 in 2016 compared to 9,000 in 2015.

The Group's water supply and sewerage services provided to customers in the region of Kampala, Uganda, were valued at 8,769,376 (USD),

representing an increase of 6.42% compared to the value of 8,238,000 (USD) recorded in 2015. This increase was due to the increase in the number of customers served by the Group, which was 10,000 in 2016 compared to 9,000 in 2015.

The Group's water supply and sewerage services provided to customers in the region of Kampala, Uganda, were valued at 8,769,376 (USD), representing an increase of 6.42% compared to the value of 8,238,000 (USD) recorded in 2015. This increase was due to the increase in the number of customers served by the Group, which was 10,000 in 2016 compared to 9,000 in 2015.

T


6.42%



The total consumption of the Group's subsidiaries for the year amounted to


8,769,376 (USD)

Water management



2016

Name of the subsidiary		Total consumption (USD)
J. C.		700
P. R.		31,800
C. B.		1,300
S. A.		2,500
D. P.	S. L. C.	30,000
A. R.		450
G. P. S.		29,000
S. S. I.		396,000
H. P. B.		3,552
A. P. R.	EDI	11,550
E. P. D.	F.	6,000
C. P. C.		960
P. R.	P.	32,984
H. R.		300
C. M. C.		120
L. M.		100
H. M.		7,415
S. T. A.		30



0 A

A. Emission of Greenhouse Gases in 2016

Category	Scope 1 (tCO ₂ e)	Scope 2 (tCO ₂ e)	Scope 3 (tCO ₂ e)	Scope 4 (tCO ₂ e)	Total (tCO ₂ e)
Manufacturing	0.000	0.001	0.000	0.12	0.12
Product	0.000	0.010	0.130	0.07	0.21
Facility	3.359	0.611	0.370	0.00	4.340
Product	0.002	0.001	0.000	0.00	0.003
Product	32.863	23.886	8.817	0.00	65.566
Product	419.839	441.936	6.187	0.00	867.962
Product	0.000	15.747	1.030	0.00	16.777
Product	3.384	2.269	1.086	0.00	6.739
Product	0.869	0.000	0.185	0.00	1.054
Product	0.000	0.000	0.000	1.34	1.34
Product	4.007	0.180	0.604	0.00	4.791
Product	0.000	0.000	0.000	0.01	0.01
Product	0.03	0.038	0.013	-	0.081
Product	0.000	0.000	0.000	0.55	0.55
Product	1.414	0.000	0.007	0.00	1.421
Product	0.002	0.000	0.000	0.00	0.002
Product	0.010	0.014	0.014	0.00	0.038



Case: Better Product of Carbon Footprint - Ga Ecosystem Center

The Ga Ecosystem Center is a large-scale ecological restoration project in Ga County, Guangxi. It aims to improve the local ecological environment and promote sustainable development. The center has implemented various measures to reduce carbon emissions, including using renewable energy, improving energy efficiency, and promoting green transportation. These efforts have significantly reduced the carbon footprint of the center, contributing to the overall goal of carbon neutrality.



Case: Transition to a Low-Carbon Ecosystem

The transition to a low-carbon ecosystem is a key goal for many organizations. This involves adopting sustainable practices across all aspects of the organization, from procurement to production. Key strategies include using green suppliers, implementing energy-saving measures, and promoting green products. By making these changes, organizations can significantly reduce their carbon footprint and contribute to a more sustainable future.

S d a e a a g e e

I 2016, F P G 80,848.14 .D P ,
F L T 3,158
() 909

I 2016, G
E


N	T	H	T							D	E	S	I	C	
			()	()	()	R	/	I	L						O
H	229.67	146	0	83.67	0	83.67	0	0	H						
C	H	738	535	0	203	0	203	0	0	H					
J	C	H	23.87	11.91	11.91	0.04	0	0.04	0	0	H				
H	G	192	75	0	117	0	0	0	117	H					
C	M	0.67	0.63	0.02	0.02	0	0	0	0.02	H	E	S	I		
B	15.3	9.6	0	5.7	0	2.5	0	3.3	H	E	S	I			
L	M	M	25.3	12	12	1.3	0	1.3	0	0	H	E	S	I	
F	B	3.37	2.08	1.08	0.21	0	0.21	0	0	H	E	S	I		
	0.84	0.75	0	0.09	0	0.09	0	0	H	E	S	I			
F	M	S	1.51	1.5	0.01	0	0	0	0	0	C	E	S	I	
H	M	63	60	3	0	0	0	0	0	S		E	S	I	
C	(B)	13	13	0	0	0	0	0	0	C	E	S	I		
C	S	0.5	0.5	0	0	0	0	0	0	C	E	S	I		
S	T	15	5	10	0	0	0	0	0	C					
L	T	78	50	28	0	0	0	0	0	C	E	S	I		
C	T	0.08	0.08	0	0	0	0	0	0	C	E	S	I		

N	E		E		
	P	A (RMB10,000)	P	A (RMB10,000)	
B	O	9.30	D	35.20	
	T	519.20	O	28.50	
	C	45.00	O	42.00	
C	B	T	0.35	M	29.36
	F	E	22.90	O	17.75
	S	A	5.00	T	1.00
D	P	T	20.00	E	100.00
	H	PS			
	A	E	1.00		13.49
G	P	T	206.00		156.00
S	S	R	218.00	E	83.00
H	P	E	1.21	S	7.14

Environmental

In 2016, the Group's total greenhouse gas emissions (Scope 1 and 2) were 33,460 tonnes of CO₂ equivalent, an increase of 2.27% from 32,710 tonnes in 2015. The Group's total greenhouse gas emissions (Scope 1 and 2) were 33,460 tonnes of CO₂ equivalent, an increase of 2.27% from 32,710 tonnes in 2015.

Environmental




Environmental

Environmental		Environmental	
N		E	
P		P	
A (RMB10,000)		A (RMB10,000)	
A	P	D	22.00
H	P	E	14.00
E	P	T	35.10
P	E	H	19.50
C	P	I	136.59
T	D	D	1.11
T	A		6.12
S	H	D	27.00
S	T	P	0.75
R	C	I	2.00
R	P	E	622.00
S	F	T	3.50
G	H	C	12.00
H		O	1.48
C	H	R	116.00
J	C	G	6.00
G	H	E	37.29
C	M	E	0.50
L	M	S	7.00
F	B	S	0.80
F	S	O	6.00
H	M	D	2.40
C	(B...)	P	4.39
S	T	E	3.00
L	T	E	8.05
C	T	E	3.00


I 2016, F P G F F P G
C C

A e a a d a a e c a e c a g e

E f g e e e g a e



Ca e: Ne c c e d a e e a e e



Ca e: Tra f a f c e c a a g e a e a



(92.7) 11 () 0.5 () 0.5 () 0. 1

I 2016, F P G

A

S

A 2016, 9 F P G

F 2016, F P G EHS

(T)

I

, F P G



Occ a a ea a d afe

F P G

I 2016, F P

I 2016 , F P 0 , 703

Safe

F P () T EHS

GB6441-86 < T S C I A F I

E E > OSHA L

()

I 2016, 20 0.044 (8) , 0.072 (13)

, 0.116 (21) () , 0.21 (38)

C 2015, 69.6%, 72.7%,


81.7%, 60.7%. A

F P


F P (PSM) API

A

B 2016, 0



A 2016



A 2016



F P [https://www.fda.gov/oc/ohrt/ohrt-report-2018.pdf](#), [https://www.fda.gov/oc/ohrt/ohrt-report-2019.pdf](#), [https://www.fda.gov/oc/ohrt/ohrt-report-2020.pdf](#), EHS

S I F P G 2016

N	T	T	I						I						IH	D	LTC
			M	S	N	N	N	I	F	L	R	L	R				
B	779	1,607,070	0	0	1	0	1	0.12	0.00	1	3	0.12	0.37	0	105		
J	169	344,110	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
P	306	708,990	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
C B	157	375,303	0	0	0	1	1	0.53	0.00	1	2	0.53	1.07	0	40		
F	210	443,520	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
S	98	250,880	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
D P	943	1,968,984	0	0	1	1	2	0.20	0.00	2	3	0.20	0.30	0	212		
A	301	660,030	0	0	0	0	0	0.00	0.00	0	1	0.00	0.30	0	0		
G P	1,155	2,310,000	0	0	0	2	2	0.17	0.00	2	3	0.17	0.26	0	84		
S S	1,860	4,464,000	0	0	3	0	3	0.13	0.00	3	3	0.13	0.13	0	350		
H P	289	622,104	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
A P	613	1,331,090	0	0	0	0	0	0.00	0.00	0	1	0.00	0.15	0	0		
H P	369	734,768	0	0	0	0	0	0.00	0.00	0	5	0.00	1.36	0	0		
E P	789	1,841,777	0	0	0	2	2	0.22	0.00	2	2	0.22	0.22	0	65		
C P	316	740,918	0	0	1	2	3	0.81	0.00	3	5	0.81	1.35	0	160		
P	1,195	2,495,160	0	0	0	1	1	0.08	0.00	1	2	0.08	0.16	0	25		
T	88	198,904	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
T	28	6,368	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
S H	292	511,704	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
S T P	95	198,360	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
C R	248	496,000	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
R P	148	340,000	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
S F	31	80,600	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
G H	541	1,137,552	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
H	660	1,326,480	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
C H	1,700	4,406,400	0	0	1	3	4	0.18	0.00	4	6	0.18	0.27	0	270		
J C H	307	677,856	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
G H	291	584,328	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
C M	19	30,818	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
F M -T	151	280,000	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
L M M	321	656,588	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
F B	18	36,860	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
	67	102,137	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
F D	89	154,784	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
H M	577	1,505,970	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
C (B...)	51	96,024	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
C S	126	245,844	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
S T	231	616,875	0	0	1	0	1	0.32	0.00	1	1	0.32	0.32	0	110		
L T	186	428,544	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		
A	213	444,744	0	0	0	0	0	0.00	0.00	0	1	0.00	0.45	0	0		
C T	4	3,392	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0		

Note: 1. 1 minor injury incident in the headquarter of the Fosun Pharma Group was included in the lost-time cases and recordable injury cases;

2. (Total, Lost-time, Recordable) Rate = (Total, Lost-time, Recordable) Number * 200,000 / Total Working Hours

N.

Table 1. Financial performance of the company in 2016, 2017, and 2018

I		F	P	G
N	P	A (RMB10,000)	P	A (RMB10,000)
F S M	I ()	9.50	P	3.80
H M	E	1.10		2.70
C (B)			A OTC	0.08
S T	P	13.00	S	5.00
L T	F	0.70	I	1.00

E ee E gage e

F P EHS
C F L
EHS
T EHS

I 2016, F P EHS T
93,431 34,913 2.15
5.75 T 22.2%
2015.



S	M	M
B	EHS EHS	R EHS
J	EHS	F ,A C ,R EHS
F	EHS	T 7 C EHS , LOTO T EHS EHS
S	EHS	T A EHS B
D P	EHS	T C C O H I () A ;E GMP A EHS ;2015 A ;F N ;
A	S	S
G P	EHS	C ,S
H P	EHS	I ,EHS
A P	S	S ,A C ,MSDS
H P	EHS	R EHS EHS ()
E P	EHS	H EHS EHS
EHS B	P EHS	1. EHS EHS ; 2. 3. EHS ; 4.C 5.I
T	S	C
T	EHS T	H
S H	EHS	H
S T P	EHS	F
R C I	EHS	A EHS EHS
R P	S	H 4 3 2 2 11
S F	L	C
H	EHS	T EHS .T 5 EHS
L M	EHS	S ,EHS
F B	EHS	S ,EHS
H M	EHS	T 11 N 2016
S T	S	R EHS ,EHS
L T	EHS	F ,A C EHS

Disclosure description: 1. The report discloses the health, safety and environmental protection quality, which is part of the working environment quality and has important effect on the Group. They include the related important performance indicators. For some key indicators which have general effect on the Group, the report has also made voluntary disclosure to some extent. 2. Six new subsidiaries, namely Wanbang Tiancheng, Wanbang Tiansheng, Fuchuang Pharma, Wen hou Geriatrics Hospital, Zhongsheng Zhongjie and Chindex Tianjin, were included in the major subsidiaries disclosed. 3. The calculation method of total number of employees in EHS section is different from the calculation method of total number of employees in Employees section in this report, the statistical scope of number of employees for EHS section is the number of employees in service.

Data description: the statistics of the data disclosed in the above sections and each table in the EHS report are conducted in accordance with related national or local regulations, industrial standards, administrative requirements or practices formulated by subsidiaries. They are derived after reasonable verification. For the data whose validity or completeness cannot be confirmed due to various objective reasons, they are denoted with "X". For the appropriate data, they are denoted with "NA".





65.6%

G .



F P G

23.92%



14.2%



(RMB100,000,000)

In 2016, the Group's cash payment to employees and on behalf of employees totaled RMB**2,196** million,

F.
50.96%

M 49.04%

T G

2016,


50.96%, 0.36%, 2.49%

R 100%


Sustainable Development Goals

Take Action

Target 12.2: By 2030, achieve substantial reduction of waste generation per capita, by halving and tripling, respectively, the global per capita incineration and landfilling rates.



Learning Development Strategy







Case: Trao đổi và Hợp tác giữa các Tổ chức Y tế và Công nghiệp 2016

S.T.P. (Strategic Technology Partnership) là một chương trình hợp tác giữa các tổ chức y tế và công nghiệp để thúc đẩy đổi mới và phát triển sản phẩm mới. Chương trình này được khởi đầu vào năm 2016 và đã thu hút sự tham gia của nhiều tổ chức y tế và công nghiệp hàng đầu.



Tổng kết và Đánh giá

C	N	C
NH S	P	FD
P	T	FP
T	T	T
T	D	E
E	()	T
M	S	S
		GDP
		GMP



Case: Tác động của các Tổ chức Y tế và Công nghiệp đối với Quản lý và Phát triển Sản phẩm

I. Mục tiêu và Phạm vi nghiên cứu: Nghiên cứu tác động của các tổ chức y tế và công nghiệp đối với quản lý và phát triển sản phẩm. Phạm vi nghiên cứu bao gồm các tổ chức y tế và công nghiệp hàng đầu.

F. S. M. C. H. F. P. G. P.

T. P. S. N. 2016. S.

G.

I.

120

C. Q. C. F. P.

T. C. E. F.



S. P.



Case: Tác động của các Tổ chức Y tế và Công nghiệp đối với Quản lý và Phát triển Sản phẩm (CML)

T. S. M. P. F. P. G.

C. (CML) L. E. M. R. M.

T.

T. P.

2-

T.

T. M.

E.

G.

T.

M.

T.

C. (CML)



E e e De e e

Perf a ce a age e


T G KPI.

F P G KPI

E B D B D

.43 G A

F P - T 0 ()6 ()6.1 ()-4 ()




S	F	P	(P)				
S	F	P	2012	2013	2014	2015	2016
T							
☒							

Employee Activities

Employee activities are important to the corporate cultural construction of Fosun Pharma Group. The Corporate Culture Working Committee (Culture Working Committee) of Fosun Pharma fully utilizes the resources of the organization, proactively organizes and coordinates among individual departments and individual subsidiary with the support from various aspects such as the labor union, administration, human resources and branding and joins efforts in the organization of various events that help invigorate employees' cultural life and jointly proceed corporate cultural constructions.

To create an innovative culture within Fosun Pharma Group, in the first half of 2016, Fosun Pharma organized the Fosun Pharma 2016 Innovation Contest named "Xingrong e-action" which aims to identify innovative talent within the Group, uncover high quality projects and to provide support for an innovative internal environment. In view of the Unicorn Potential Award and Business Innovation Award, the contest has received a total of 98 pieces of work, with more than 900 audiences voting to ultimately decide the winner.

In 2016, the labor unions of Fosun Pharma and its subsidiaries organized over 350 cultural and sports activities, including various festival caring events for employees such as Chinese New Year, Lantern Festival, International Women's Day, Children's Day, Mid-Autumn Festival, Chung Yeung Festival, Children's Day, high temperature allowance, birthday parties, employee physical examination and street market activities, as well as various employees' club activities. Fosun Pharma Group has established 12 employees' clubs which will organize various activities welcomed by the employees regularly. Meanwhile, each club proactively participates in neighborhood activities and community interaction through the



The Meeting is now online

G...P... F...P... CME...
...O...
...A...T...A...
...A...
T... G...P...
...D.C...D...H...M...



P. b c e fare c y b

C e ce

>300 e
V e e e a
a c e

>90 e
P. b c e fare e a
a a d e a
c a

F e g a d e c

1 P e c

H



Scale of Service

In 2016, the total number of services provided was RMB2.99.*

Based on the data collected from the survey, the scale of service is as follows: The number of services provided in 2016 was 14 million, which is an increase of 8.3% compared with 2015. The total number of services provided in 2016 was 14 million, which is an increase of 8.3% compared with 2015.

*Note: The number of services provided in 2016 was 14 million, which is an increase of 8.3% compared with 2015.



In 2016, the total number of services provided was RMB2.99.

RMB2.99

8.3%

RMB 2.76 2015

Creation of New Services

According to the survey, the creation of new services is as follows:

The number of new services created in 2016 was 14 million, which is an increase of 8.3% compared with 2015. The total number of new services created in 2016 was 14 million, which is an increase of 8.3% compared with 2015.

F P
T
I 2016, F A S D C T
C
I D OA F P F A S
D
A 42

Fd car, Ad ya S er De ar e

T
C B D F A 2016,
A S D C F
C
C
I 2016, F A S
D F P A C O T H P B M D T
E C F P T H P C M R
S F F A A S S D D I
F A S D 23
T F A S D
M F A S D
I 2016, F A S D
ISO19600 C M S G

C C ar

F P
RMB7.97 (I 2016, F P G).
I crea ed de c c ar c e
erfec g e FUTURE STAR
F P G F P G
P G F T RE STAR 1998. F

F F da

I 2016, F P RMB5.00 F F A S B C.C.T
L S D F F D T A T


Targeted P er A e a

F P G C



I 2016, F P
F F

RMB5



G
C , F P G
I 2016, F P
RMB6.45
F P , A H P RMB1,000,000 C
A A (F F D T)
F P L S F C P C
RMB150,000 29 (F I 2016,
10 ; C P :15).
J C H F P 60
100 RMB5,000,000.
T P C H 9
B J A P 30
RMB30,000 D L T C F
M RMB50,000 J C F 207
H C .17 O 2016 P P A D
A B G 2016, G P RMB60,000 T
H J F A P C C F D
A G C C D G C , C C C F I R
I Q D . I 2016, C R I
RMB150,000 Q D



L P I
M C F
P
C M

Case: Joined force with Shanghai Charity Foundation to provide support to patients suffered from cancer

On 9 September, the charity day, Shanghai Charity Foundation, Fosun Foundation and Shanghai Symphony Orchestra jointly organized the charity concert of "Fosun Charity Night: Let Love Fill the New World". All the donations in the event were collected through various mobile and internet charity platforms such as Tencent, Alipay, official WeChat account of Fosun Foundation (fosunfoundation) and the official website of Shanghai Symphony Orchestra, and were donated to Shanghai Charitable Cancer Research Center to finance the doctors and scientific researchers in Shanghai who devote in cancer clinical research, so as to work out the best treatment solutions for patients suffered from cancer as soon as possible.

Case: Double Thousand Actions provided timely support and care to all patients suffered from tuberculosis

On 22 March, at the promotion event of World Tuberculosis Day, Chinese Antituberculosis Association established the Chinese Anti-tuberculosis Non-profit Foundation and jointly launched the Chinese Anti-tuberculosis Non-profit Foundation - Double Thousand Actions assistance project for tuberculosis with Fosun Foundation and Hongqi Pharma (a subsidiary of Fosun Pharma). The Double Thousand Actions project will last for five years from 2016 to 2020. At least 1000 needy patients suffering from tuberculosis can be helped each year and the funding for each patient would not be less than RMB1,000. Fosun Foundation collaborates with Hongqi Pharma, a subsidiary of Fosun Pharma, to provide continuous sponsorship in the form of funding and medicine etc.

On 27 April, the 2016 National Academic Meeting of Chinese Antituberculosis Association was held in Zhuhai, Guangdong Province, and the unveiling ceremony of Chinese Anti-tuberculosis Non-profit Foundation took place at the opening ceremony.

Case: Organization of the 2nd Climb for Charity Competition by Fosun Pharma with the donation allocated to Qixiang Institute of Child Development

In February, the Climb for Charity Competition co-organized by Fosun Foundation and Fosun Pharma was held in the headquarter building of Fosun Pharma. About 22 teams participated the activity with participants covering staff of Fosun Pharma and their families, media as well as other stakeholders. All teams completed the competition within required time. The competition finally raised a total donation amount of RMB66,000.

A meeting to allocate the donation from the Climbing for Charity Competition was held in April. Six project leaders of the public welfare projects which applied for the donation presented their projects. After the voting, the Family of Children with Special Needs Rehabilitation Support Program by Shanghai Qixiang Institute of Child Development was granted the donation.

Case: Walking for Love the Shanghai United Walkathon Volunteer Event was held again

In April 2016, the Shanghai United Walkathon Volunteer Event was held again. Participants and volunteers of Fosun Pharma participated the event with full enthusiasm despite of the bad weather. With the support, accompany and encouragement of teammates and the Company's volunteers, the whole 12-hour walkathon covering a total of 50 kilometers was completed successfully with full love. Fosun Pharma volunteers have participated in the Shanghai United Walkathon charity event for four successive years and raised over RMB300,000 for supporting the children nutrition in poor areas, rural children's reading, children with autism, quality training for migrant children as well as other sectors.

Case: the Bang Program Trying the best to participate in public welfare activities

As the extension of the Company's core value of self-improvement, teamwork, performance and contribution to society as well as the inheritance of the public welfare mission of trying the best to participate in public welfare activities, the Bang Program public welfare project team expanded the activity scope in 2016 to further cover more students in poverty and fundamental hospitals in remote areas. Through preliminary study and careful selection, in 2016, the Bang Program public welfare project team of Wanbang Biopharma visited Yuanyang County and Zhengzhou in Henan Province, Jingxing County in Hebei Province and Suining County in Jiangsu Province, carried out in-depth interaction with the grassroots, supported the local education and healthcare, and further improved the local educational and medical conditions and levels, which was well recognized and encouraged by the supported students in poverty areas, fundamental medical works and experts participated in the activities.



Volunteer Tea

T F P 100 .S
2010, F P
F P
H
S
I
F P S C I .S 2010,
E
F P T T M D S C I J
Q T M D S C I
F F L S C I
T F P S S M S (F P M D),
D
L C L T 25 T F P 17,000
30
C H 10 L N
1,100 G H S S A H
3 5 T G H

C Service

I 2016, G 100
A P O H 2016. J C F G C P S
J T H C C P S T H
C B D P C
N T M
T
D 90
T 2016, G H
5,000 2 3 M G H T E P
J C H M A P R C F S
S 65- M T P P R C F S
S C 65 C H I 2016,
21 T
C H A
C H



T 90
>90



G H



O H D C
H R D
C G G

D F P (). 2016

E P T R				A (RMB10,000)	B			
				()				
					M D F L S	RMB1,500,000	S	M T J L S T J C
F P	P	2016 F P C	S F F	500	D F P TB	RMB1,000,000	C A F P	A 2016. H
					S RMB1,000			
					D S	RMB400,000	S C R C F C	2016
D P IT				H D C 1.5	D C	7	H	D
B				S M	S	M S	M S	
				R C H C P C S H D T M C S C H J C J S C P J C H S C S J C P T H	P	D	O R C	
M D &				30				
					T S	B J Q N B	T M	B H
D C P				D 60				
S F				G 0.5				
T F				H 4	12			
H P A				R C F C 18.8	H P	F C		
F				E 2	F	B R	C	
P F				7 0.4	8 (T			





M	F	P	G		
I	2012 ()	2013 ()	2014	2015	2016
N	6.05	6.84	7.21	7.86	9.19
B	(RMB/)*	(RMB/)	0.92	1.07	1.21
B	0.80	0.90			

Cash	Financial	Provision	Goodwill	(RMB10,000)	
	2012 (RMB10,000)	2013 (RMB10,000)	2014	2015	2016
Receivables	734,078	999,641	1,202,553	1,260,865	1,462,882
Inventory	186,598	214,062	192,501	234,662	212,540
Other receivables	203,599	281,883	239,435	329,717	339,942
Prepaid expenses	9,725	10,436	34,047	10,666	19,511
Long-term receivables	1,020	1,692	1,676	3,200	2,298
Others	282	1,045	85	362	974
Total	212,304	290,627	271,805	337,183	357,155
Liabilities	28,376	50,632	34,821	50,117	35,021
Notes payable	183,927	239,995	236,984	287,066	322,134
Accounts payable	156,392	202,706	211,287	246,009	280,584
Other payables	27,536	37,289	25,697	41,057	41,550
Total	78,900	105,080	126,821	143,449	163,136
Debt	333	424	735	847	797

[illegible]

S c a l d c a 1

.....

.....

.....

.....

.....

.....

.....

Core data

Environmental Health Safety (EHS) Key Indicators Performance

Indicator	2014	2015	2016
Total (/)	421,765,752	424,467,622	478,175,186
Energy (/)	51,835,011	52,209,518	58,815,548
Total (/)	122,713,255	121,204,106	126,874,724
Cost (/)	174,548,266	173,413,623	185,690,272
Environment RMB10,000 (/)	171	157	126.93
Total (/)	8,377,364	8,716,937	8,769,376
RMB10,000 (/RMB10,000)	8.23	7.89	5.99
Incident (RMB10,000)	3,200	3,166	3,346
Incident (RMB10,000)	1,200	2,156	2,027
Occupational (RMB10,000)	2,000	1,010	1,319
Total (/)	136,637	871,123	563,081
Total (/)	5,677,448	6,285,061	6,785,400
Total (/)	50,258	65,597	80,848.14
Total (/)	15,757	15,187	16,325
L	N	0.424	0.116
R	N	0.533	0.21
O	14.88%	12.58%	14.89%
Health Safety (RMB10,000)	2,060	4,505	3,155
Total (/)	N	71,474	93,431
D (/)	N	4.71	5.75
Energy COD (/)	440	488	490
Energy NH3-N (/)	60.94	56.00	60.55
Energy (/)	90	411	466
Energy (/)	318	408	485
Energy (/)	130	110	19

Feedback F 1

D R ,

T ! I C S R R

:

C : S L T : +86 21 33987125

P : P B P R D () B A,
C T P , N . 1289 R , S P : 200233

E : @ : :

S F P (G) C „ L . 2016 C S R R F F

N :

E :

R :

T :

E :

F O S :

1 H ?

2 H S F P (G) C „ L . ?

3 H S F P (G) C „ L . ?

4 H S F P (G) C „ L . ?

5 H S F P (G) C „ L . ?

Feedback e 2016 F Par a S ca Re

b Re 1

L Hef , E ec e V ce-C a a a d S e c r e a r , G e r a f e S a g a
F e d e r a l e f E c c O r g a a

T 2016 F P S R R

I F P
F G H

Z a g H a - E r , F . d e r f R a g C S R R a g (R K S)

A F P
T

F P F

C e W e e g , G e r a M a a g e r f G d e B e e (B e g) M a a g e e
C „ g C „ L d .

T 2016 F P S R R

C R
M
F P
O

F F P
E

D N 2030 A S
C F D C
C F P A

C

Table fC a, Name

F	S
J B G C _v L	B
S C B C _v L	C B
H F P C _v L	F
S P C L	P
J P C _v L	J
S S B	
P C _v L	S
J H P C _v L	H P
C P C _v L	P
S H P C _v L	H P
C C P C _v L	C P
S S (H) B E C _v L	S S
G P C _v L	G P
S H P C _v L	H P
J A P C _v L	A P
D A B C _v L	A
H D P C _v L	D P
C P R I C _v L	C R I
S H B C _v L	S H
S S T P C _v L	S T P
S E P C L	E P
S G C _v L	S
A J C H	J C
G H C _v L	G H
S H C _v L	H
F C C H C _v L	C H
S F L M M S C _v L	L M
S F B B C _v L	F B
B (S) C _v L	B

F	S
T C M T C _v L	C M
C (B) I T C _v L	C (B)
C M L	CML
C I , I	C , CHD
A L L	A
H M I C _v L	H M
S T T C _v L	S T
S L B T E C _v L	L T
S F M S C L	F M
I S , I	I S
S F H T (G) C	F G
L	
S F P C _v L	F P
S B , I	S B
S F P T	F P
D C _v L	
A T I	A T
L G	L
A , I	A
C F P R C _v L P F	
C R P C _v L	R P
C S I T C L C S	
C T I T C L	C T
S F H I (G) C _v L	F H
S , I	S
G E C	GE
H T P C _v L	T
G P L	G P

Ter g e

T	D
GRI	A G R I
FSC	A F S C
EHS	A E ,H S
CAPA	A C A &P A
FDA	A F D A (S)
HO-PQ	H O PQ Q , P PQ. I
TO	A T O
GMP	A G M P
GMP	A C G M P
OOS	A O S S
SOP	A S O P
GCP	A G C P
CSR	A C -S -R
A	A
CME	T O M T P G P 2014
IT	A I T
NGO	A N -G O
CE	A E C F CE CE E
T	T - G E T G
ISO13485	T Q M S M D I O
I	I

S
62-6.303 T (S)-546-S

Third Party Evaluation

D
PRC
T
C
F P
C
F P G
F P
M
EHS
P
A
F P
A
A
C
F P
SDG (SDG) N 2020
I F P
F P
C
C
F P
C



C B C S D

Q

G da ce ca f g ca re b e f a ce (GB 36002)

S N	C	P
Dec	Ma g Pr ce a d Sv. c e (Z-1)	
-1-1	T	15-17
-1-2	P	3
-1-3	M	17
-1-4	E	23-25, 34-39
-1-5	M	23-25
-1-6	M	24-30
-1-7	M	23, 26-31
-1-8	I	27-31
-1-9	M	24, 100, 105-111
-1-10	M	19-20, 24
-1-11	M	23-25
-1-12	M	19-22
C a d c a g (R-1)		
R-1-1	R	13, 41, 55, 80-81, 98, 101
R-1-2	R	99, 104-105
R-1-3	R	N/A
R-1-4	R	38-39
R-1-5	R	98
R-1-6	R	98-99
Ec c, ca a dc a g (R-2)		
R-2-1	D	52-53, 104-105
R-2-2	T	38, 104
Ba c c e a d g a (R-3)		
S N	C	
R-3-1	R	99, 104-105
R-3-2	M	92-100
R-3-3	M	98-99
R-3-4	M	98-99

G da ce ca f g ca re b y e f a ce (GB 36002)

S	C	P
N		
E e a d a re a (L-1)		
L-1-1	N	98-99
L-1-2	N	92-99
L-1-3	P	92-99
L-1-4	E	98-99
L-1-5	N	98-99
L-1-6	N	98-99
L-1-7	P	22, 98-99
L-1-8	T	98-99
L-1-9	M	50-51
W g c d a d ca r ec (L-2)		
L-2-1	T	58-60, 80-84
L-2-2	P	80-84, 100
L-2-3	R	98
L-2-4	M	98-100
L-2-5	D	38-39
L-2-6	E	38-39, 98-99
L-2-7	N	98-99
L-2-8	P	92-100
L-2-9	R	92-100
L-2-10	R	98-100
L-2-11	C	98-99
De a a c e a d c ec ed c (L-3)		
S	C	
N		
L-3-1	M	99
L-3-2	E	99, 104-105
L-3-3	M	98-99, 104-105
L-3-4	E	98-99, 104-105
L-3-5	T	21-22, 104-105
Occ a a ea a d a fe (L-4)		

G da ce ca f g ca re b e f a ce (GB 36002)

S	C	P
N		
L-4-1	T	58
L-4-2	C	80-81
L-4-3	T	80
L-4-4	C	81
L-4-5	P	83-84
L-4-6	R	81-82
L-4-7	S	81
L-4-8	E	81
L-4-9	M	81
L-4-10	P	86-88
L-4-11	P	89

De e e a d a g f a e (L-5)

L-5-1	P	93-97
L-5-2	M	98-99
L-5-3	P	98-99

P e e f a (H-1)

H-1-1	T	58-59
H-1-2	T	71-74
H-1-3	M	71-74
H-1-4	M	71-74
H-1-5	T	71-74
H-1-6	M	71-74
H-1-7	P	75-76
H-1-8	S	75-76
H-1-9	P	60

T e e f a a b e e a ce (H-2)

H-2-1	T	60-63
H-2-2	M	60-63
H-2-3	R	64-65
H-2-4	M	64

G da ce ca f g ca re b e f a ce (GB 36002)

S	C	P
N		
H-2-5	M	65
H-2-6	M	64-65, 72-73
H-2-7	M	78
H-2-8	P	58-61
H-2-9	M	57-89

A e a a da a e c a e c a ge (H-3)

H-3-1	T	79-80
H-3-2	M	79-80
H-3-3	M	79-80
H-3-4	E	60-65
H-3-5	M	(GHG) 79
H-3-6	E	64-65
H-3-7	M	79-80
H-3-8	T	60-61
H-3-9	M	79
H-3-10	M	N S

E e a e c , b d e e a d e e c e f e a a a b a (H-4)

H-4-1	T	79
H-4-2	T	79
H-4-3	C	79
H-4-4	I	65, 79
H-4-5	M	79
H-4-6	T	61-77
H-4-7	M	N E
H-4-8	T	N A
H-4-9	T	78
H-4-10	E	79

G da ce ca f g ca re b e f a ce (GB 36002)

S	C	P
N	M	
H-4-11		79
A e c n e (G-1)		
G-1-1	T	104-105
G-1-2	T	105
G-1-3	T	105
G-1-4	M	104-105
G-1-5	M	19
G-1-6	E	104-105
G-1-7	T	104-105
G-1-8	T	N S E
G-1-9	T	104-105
G-1-10	M	104-105
Fa r C e e (G-2)		
G-2-1	T	48
G-2-2	P	N S
G-2-3	M	48
G-2-4	M	N S E
G-2-5	R	98-99
P r e f ca re b e e a e c a (G-3)		
G-3-1	T	50
G-3-2	M	50
G-3-3	D	28
G-3-4	M	N S
G-3-5	M	N S
G-3-6	F	50
Re e f f e r e n c e (G-4)		
G-4-1	T	34
G-4-2	34	

G da ce ca f g ca re b y e r f a ce (GB 36002)

S	C	P
N	M	
-3-2		44-46
C e e ce, a d c a a d d e a d g (X-4)		
-4-1	M	47
-4-2	T	47
-4-3	T	N S
-4-4	T	48
-4-5	A	27, 48
-4-6	R	27, 48
-4-7	T	27, 47-48
C e l f a P e c a d P a c (X-5)		
-5-1	R	47-48
-5-2	N	47-48
-5-3	L	47-48
-5-4	C	47-48
-5-5	N	47-48
-5-6	M	47-48
-5-7	A	22
-5-8	P	22
-5-9	P	22
A c a f b a c e ce (X-6)		
-6-1	I	48
-6-2	P	98
-6-3	T	47
-6-4	M	48
-6-5	F	N E

G da ce ca f g ca re b y e f a ce (GB 36002)

S	C	P
N	S	47, 53
-6-6		
Ed ca a dA are e (X-7)		
-7-1	C	86-88
-7-2	C	48
-7-3	C	48
-7-4	C	27
-7-5	C	27
-7-6	C	N S
-7-7	C	N S
-7-8	C	N S
-7-9	C	27
-7-10	C	N S
S ca Par c a (S-1)		
S-1-1	C	108
S-1-2	F	N E
S-1-3	P	105, 107
S-1-4	M	104-105
S-1-5	I	108
S-1-6	M	108
Ed ca a dC are (S-2)		
S-2-1	F	106
S-2-2	M	106
S-2-3	A	107
S-2-4	P	
S-2-5	A	
E e e a d de e e (S-3)		
S-3-1	E	92
S-3-2	T	93-94
S-3-3	M	50
S-3-4	M	92

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

G4 ba Re 11 g l a e G4 l d ca 1 l de

N	C	P
G4 GENERAL STANDARD DISCLOSURES		
STRATEGIC AND ANALYSIS		
G4-1*	C (CEO,)	3
G4-2	P	3, 4, 16-17, 139
ORGANIZATIONAL PROFILE		
G4-3*	R	F C , 11, 13, B C
G4-4*	R	12, 44
G4-5*	R	B C
G4-6*	R	12, 18
G4-7*	R	4, 11, 19
G4-8*	R	18, 35-37, 42, 44
G4-9*	R	12
G4-10*	.R NGC .R .R .R .R	92-93, 99
G4-11*	R	98
G4-12*	D	50, 78
G4-13*	R	14, 27-30, 50
G4-14*	R	46, 104-105
G4-15*	L	29-30
G4-16*	L	31
IDENTIFIED MATERIAL ASPECTS AND BOUNDARIES		
G4-17*	.L .R	4, 116-117
G4-18*	.E .E C	A B R P D R 23, 117, 139
G4-19*	.L	A 23

*Note: The term "aligned" refers to the GRI4 General Standard Disclosure categories and the GRI4 card standard. It becomes relevant for each category based on the GRI4S disclosure category.

G ba Re g l a e G4 l d ca l de

N	C	P
G4-20*	F A A B	23
G4-21*	F A A B	23
G4-22*	R	112-113
G4-23*	R S A B	4, 12, 117

STAKEHOLDER ENGAGEMENT

G4-24*	P	26-30
G4-25*	R	26-30
	R	
G4-26*		26-30
	R	
G4-27*	R	26-30
	R	

REPORT PROFILE

G4-28*	R ()	4
G4-29*	D ()	4
G4-30*	R ()	4
G4-31*	P	115
G4-32*	R R GRI C I () R E A R GRI	4, 131-138
G4-33*	R I R R	4, 121, 140-141

GOVERNANCE

G4-34*	R I	19-20
G4-35	R	19-20
G4-36	R	19-20
G4-37	R I	23-25
G4-38	R	19-20
G4-39	R C ()	19-20
G4-40	R	19-20

N	C	P
G4-41	R	19
G4-42	R	17, 44, 58, 104
G4-43	R	34-39, 56-91, 104
G4-44	R	19-22
G4-45	R	3, 19, 27-30
G4-46	R	19-22
G4-47	R	21, 35-38, 104
G4-48	R	19
G4-49	R	19
G4-50	R	19
G4-51	R	38-39, 59, 98
G4-52	R	19
G4-53	R	

G ba Re g l a e G4I d ca I de

N	C	P
G4-EC2	F	58-59
G4-EC3	C	39, 98
G4-EC4	F	
Ma e P e e ce		
G4-EC5	R	39, 90
G4-EC6	P	92-93
I d e c Ec c l a c		
G4-EC7	D	105-107
G4-EC8	S	34-35
P c e e P a c e		
G4-EC9	P	46-48

ENVIRONMENTAL

Ma e a

G4-EN1	M	B	O																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																														</
--------	---	---	---	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	----

E e g

G4-EN3	E	C					T	O																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																								
--------	---	---	--	--	--	--	---	---	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Wa e r

G4-EN8	T			B	S																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																									
--------	---	--	--	---	---	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

B d e r

G4-EN11	O	S	O	L	M	I	O A	T	P	A	A	A	O	N S	E
	H	B		O	P	A									
G4-EN12	D	O S		I	O A		P	A S		O B			I	N S	E
	P	A	A A	O H	B		O	P	A						
G4-EN13	H	P	O R											N S	E
G4-EN14	T	N	I C N R	L S	A N	C		L S		H		I		N S	E
	A	A	B O	B L	O E	R									

N	C	P
E		
G4-EN15	D. G. G (G)E . . . (S 1)	79
G4-EN16	E I . G G (G)E . . . (S 2)	79
G4-EN17	O I . G G (G)E . . . (S 3)	62, 79
G4-EN18	G ()	N S . .
G4-EN19	R ()	N S . .
G4-EN20	E ()	N S . .
G4-EN21	N , ,	71
E , e a dWa e		
G4-EN22	T	72
G4-EN23	T	75-76
G4-EN24	T	N S . . E
G4-EN25	B C I, II, III	N S . . E
G4-EN26	I	N S . . E
P d c a dSe ce		
G4-EN27	E	60
G4-EN28	P	66-70
C a ce		



Globally Guided by the

N	C	P
LABOR PRACTICES AND DECENT WORK		
Environment		
G4-LA1	T	93, 99
G4-LA2	B	38-39, 98
G4-LA3	R	98
Labour/Management Relations		
G4-LA4	M	98
Occupational Health and Safety		
G4-LA5	P	83-84
G4-LA6	T	80-83
G4-LA7		83-84
G4-LA8	H	86-88
Training and Education		
G4-LA9	A	95
G4-LA10	P	93-97
G4-LA11	P	98
Derivatives and Other		
G4-LA12	C	93
Environmental Effects of Work and Materials		
G4-LA13	R	38-39, 98
Senior Management of Labour Practices		
G4-LA14	P	N/A
G4-LA15	S	N/A, E
Labour Practices Governance Mechanisms		
G4-LA16	N	98
HUMAN RIGHTS		
Issues		
G4-HR1	T	N/A
G4-HR2	T	93-97

Gaba Re-Engineering G4I dca-1 de

	N	C	P
A-1-c e-1-e Be a-1			
G4-SO7	T		N S... E
C a ce			
G4-SO8	M		N S... E
S er A e e-1-f-1 ac-1 S ce-1			
G4-SO9	P		N S...
G4-SO10	S...		50,78
Gr e a ce Mec a-1 f-1-1 ac-1 S ce-1			
G4-SO11	N		N S... E

PRODUCT RESPONSIBILITY

C-1-1 er Hea-1 a d Safe-1			
G4-PR1	P		N S...
G4-PR2	T		N S... E
Pr d-1 a d Ser-1 ce Labe-1 g			
G4-PR3	T		44-46, 48
G4-PR4	T		N S... E
G4-PR5	R		27,31,53
Mar-1 e-1 g C-1-1 ca-1			
G4-PR6	S		N S... E
G4-PR7	T		N S... E
C-1-1 er Pr-1 ac-1			
G4-PR8	T		N S... E
C a ce			
G4-PR9	M		N S... E



I A S 12- 50 F P D

F P RMB300,000 S

I A

L H F P


T H

Assurance Statement of SGS



ASSURANCE STATEMENT

SGS-CSTC STANDARDS TECHNICAL SERVICES CO., LTD. SHANGHAI



Assurance Statement of SGS

The assurance team was assembled based on their knowledge, experience and qualifications for this assignment, and comprised auditors registered with Sustainability Reporting Assuror, SAI

auditor, CGA-IFAC 14001 Lead Auditor, CGA-IFAC 18001 Lead Auditor, and pharmaceutical industry experts etc.

Registered SA-8000 Lead Auditor, and pharmaceutical

ASSURANCE OPINION

Based on the methodology described and the verification work performed, we are satisfied that the information and data contained within 2016 CSR Report verified is accurate, reliable and

On the basis of the methodology described and the verification work performed, we are satisfied that the information and data contained within 2016 CSR Report verified is accurate, reliable and

provides a fair and balanced representation of FOSUNPHARMA's sustainability activities and relevant performance in 2016. The assurance team is of the opinion that the Report can be used by the Reporting Organization's Stakeholders.

In our opinion, FOSUNPHARMA has chosen an appropriate option of assurance for this reporting.

their report

REPORTING INITIATIVE REPORTING GUIDELINES (2013) CONCLUSIONS FINDINGS AND RECOMMENDATIONS

GLOBAL FINDINGS

Stakeholder Inclusiveness

Stakeholder Inclusiveness
FOSUNPHARMA had effectively identified the stakeholder. Established the channel and platform for stakeholder's communication and inclusiveness and took different ways to communication and exchange information.

Sustainability Context

Sustainability Context
FOSUNPHARMA had presented the different sustainability issues and how they relate to the organization's environmental and social conditions and combined the performance in the wide context.

Materiality

FOSUNPHARMA had presented the different sustainability issues and how they relate to the organization's environmental and social conditions and combined the performance in the wide context. The organization's report included coverage of material aspects and boundaries significant economic, environmental and social impacts, to enable stakeholders to assess the organization's performance in the reporting period. SGS recommended that the organization should include the coverage of external entities with significant impacts while collected information.

Completeness

FOSUNPHARMA's report included coverage of material aspects and boundaries significant economic, environmental and social impacts, to enable stakeholders to assess the organization's performance in the reporting period. SGS recommended that the organization should include the coverage of external entities with significant impacts while collected information.

Balance

FOSUNPHARMA's report represented the balance principle with no negative aspects. SGS recommended that the organization could describe in detail how to take measures.

Comparability

FOSUNPHARMA's report included coverage of material aspects and boundaries significant economic, environmental and social impacts, to enable stakeholders to assess the organization's performance in the reporting period. SGS recommended that the organization should collect and disclose, which could help stakeholders to understand the improvement performance year by year, and against other organizations (on a field, such as pharmaceutical, hospital performance).

Assurance Statement of SGS

Accuracy

FOSUNPHARMA's information in the report was accurate, capable to reveal more qualitative and quantitative information for stakeholders.

Timeliness

Assurance to know that the data and information was on a regular schedule and available in time. FOSUNPHARMA will report on a regular schedule with one year to assure the good timeliness.

Clarity

Report was presented different ways with words, charts, graphics and pictures, also describe with actual cases as well to ensure the stakeholders understanding easily. SGS recommended that same content in the report should be revised and improved on length and content.

According to analyzing and disclosing methods managing and controlling in CSR report, the data and information was reliable. SGS recommended that data of energy saving project do not use the estimate of the data.

SGS Technical Services Co., Ltd. Shanghai Branch

Shanghai, China

Reliability

Through information and data collecting, recording and controlling in CSR report, the data and information was reliable. SGS recommended that data of energy saving project do not use the estimate of the data.

Signed

For and on behalf of SGS CSTC Standards



Ben Tsang
Director, China and Hong Kong
Certification and Business Enhancement
28-Mar-2017

B-11/F, No. 900, Yishan Road, Xuhui District,
WWW.CN.SGS.COM

FOSUNPHARMA



Follow us on WeChat

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Building A, Fosun Hi-Tech Park, No.1289 Yishan Road, Xuhui District, Shanghai, P.R. China, 200233

Tel: +86 21 3398 7000

Fax: +86 21 33987020

For more information, please visit www.fosunpharma.com